North America Gastroparesis Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. North America Gastroparesis Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. North America Gastroparesis Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. North America Gastroparesis Market Regional Analysis

6.2 North America Gastroparesis Market Revenue 2018-2027 (US$ Million)

6.3 North America Gastroparesis Market Forecast Analysis

7. North America Gastroparesis Market Analysis – by Type

7.1 Idiopathic

7.1.1 Overview
7.1.2 Idiopathic: North America Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

7.2 Diabetic

7.2.1 Overview
7.2.2 Diabetic: North America Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

7.3 Post-Surgical

7.3.1 Overview
7.3.2 Post-Surgical: North America Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

8. North America Gastroparesis Market Analysis – by Drug Class

8.1 Prokinetic Agents

8.1.1 Overview
8.1.2 Prokinetic Agents: North America Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

8.2 Botulinum Toxin Injections

8.2.1 Overview
8.2.2 Botulinum Toxin Injections: North America Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

8.3 Antiemetic Agents

8.3.1 Overview
8.3.2 Antiemetic Agents: North America Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

9. North America Gastroparesis Market Analysis – by Distribution Channel

9.1 Retail Pharmacies

9.1.1 Overview
9.1.2 Retail Pharmacies: North America Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

9.2 Hospital Pharmacies

9.2.1 Overview
9.2.2 Hospital Pharmacies: North America Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

10. North America Gastroparesis Market – North America Analysis

10.1 Overview

10.2 North America

10.2.1 North America Gastroparesis Market Breakdown, by Key Country, 2021 and 2027 (%)
10.2.1.1 North America Gastroparesis Market – Revenue and Forecast Analysis – by Country
10.2.1.1 US: North America Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.1.1 US: North America Gastroparesis Market Breakdown, by Type
10.2.1.1.2 US: North America Gastroparesis Market Breakdown, by Drug Class
10.2.1.1.3 US: North America Gastroparesis Market Breakdown, by Distribution Channel

10.2.1.2 Canada: North America Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.2.1 Canada: North America Gastroparesis Market Breakdown, by Type
10.2.1.2.2 Canada: North America Gastroparesis Market Breakdown, by Drug Class
10.2.1.2.3 Canada: North America Gastroparesis Market Breakdown, by Distribution Channel

10.2.1.3 Mexico: North America Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.3.1 Mexico: North America Gastroparesis Market Breakdown, by Type
10.2.1.3.2 Mexico: North America Gastroparesis Market Breakdown, by Drug Class
10.2.1.3.3 Mexico: North America Gastroparesis Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Allergan Plc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 ANI Pharmaceuticals, Inc.

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Cinrx Pharma, LLC (Cindome Pharma)

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 EVOKE PHARMA

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Ipca Laboratories Ltd.

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Johnson and Johnson Services, Inc.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 NEUROGASTRX, INC.

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Pfizer Inc.

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 TEVA PHARMACEUTICAL INDUSTRIES LTD

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

North America Gastroparesis Market

Analysis By Type (Idiopathic, Diabetic, Post-Surgical, and Others), Drug Class (Prokinetic Agents, Botulinum Toxin Injections, and Antiemetic Agents), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others)